Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Byung Wan Lee
Severance Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Samsung Medical Center
Changwon, South Korea
- Soonchunhyang University Hospital
Cheonan, South Korea
- Keimyung Dongsan University Medical Center
Daegu, South Korea
- Hanyang University Guri Hospital
Guri-si, South Korea
- Catholic University of Seoul St.Mary'S Hospital
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Severance Hospital
Seoul, South Korea
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Apr 2019
- Primary completion
- 2 Jul 2020
- Completion
- 2 Jul 2020
- Last update posted
- 29 Apr 2021
- Registered enrollment
- 51
- Registry id
- NCT03910361
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.